Arbutus BiopharmaABUS -2.24%53 Quick Ratio is 54.26 as of Mar. 2026, which is 378% above its 10-year median of 11.35. GuruFocus rates ABUS with a GF Score™ of 53/100 and a GF Value™ of $51.42 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,417 Biotechnology companies, Arbutus Biopharma ranks better than 98.66% on this metric.
Arbutus Biopharma has a quick ratio of 54.26. It generally indicates good short-term financial strength.
The historical rank and industry rank for Arbutus Biopharma's Quick Ratio or its related term are showing as below:
ABUS'
s Quick Ratio Range Over the Past 10 Years
Min: 4.6 Med: 11.35 Max: 54.26
Current: 54.26
During the past 13 years, Arbutus Biopharma's highest Quick Ratio was 54.26. The lowest was 4.60. And the median was 11.35.
ABUS's Quick Ratio is ranked better than 98.66% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs ABUS: 54.26
Arbutus Biopharma (NAS:ABUS) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Arbutus Biopharma Quick Ratio Related Terms
Arbutus Biopharma Quick Ratio Historical Data
* Premium members only.
The historical data trend for Arbutus Biopharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arbutus Biopharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arbutus Biopharma Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Arbutus Biopharma's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Arbutus Biopharma's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arbutus Biopharma (ABUS) has a Quick Ratio of 54.26 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Arbutus Biopharma and its competitors. This is 378% above median its historical median of 11.35. Over the past decade, Arbutus Biopharma's Quick Ratio has ranged from 4.60 to 54.26. According to the industry distribution chart, Arbutus Biopharma ranks #19 out of 1417 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Arbutus Biopharma's Quick Ratio too high?
Arbutus Biopharma's current Quick Ratio of 54.26 is 378% above median its 10-year median of 11.35. Over the past 10 years, this metric has ranged from a low of 4.60 to a high of 54.26. The Biotechnology industry median Quick Ratio is 3.60. Arbutus Biopharma's value of 54.26 is 1407.2% above this industry median. Based on the distribution chart, Arbutus Biopharma ranks #19 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arbutus Biopharma has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Quick Ratio compare to SPRY and KURA?
According to the Biotechnology industry distribution chart, Arbutus Biopharma ranks #19 out of 1417 companies for Quick Ratio. This places Arbutus Biopharma in the top 1% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Arbutus Biopharma's value of 54.26 is 1407.2% above this benchmark. Historically, Arbutus Biopharma's own Quick Ratio has ranged from 4.60 to 54.26 over the past decade. While the company's 10-year median is 11.35 vs. the industry median of 3.60, Arbutus Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arbutus Biopharma's current Quick Ratio of 54.26 is 1407.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Arbutus Biopharma and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arbutus Biopharma's current Quick Ratio is 54.26, which is 378% above median its own 10-year median of 11.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $51.42, compared to a current price of $4.36 — trading 91.5% below its estimated fair value. The current Quick Ratio is 54.26, which is 378% above median its 10-year median of 11.35 and 1407.2% above the Biotechnology industry median of 3.60. Arbutus Biopharma's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current Quick Ratio is 54.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arbutus Biopharma (ABUS) Overvalued in 2026?
Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued.
The current stock price of $4.36 is trading 91.5% below its estimated GF Value™ of $51.42.
GuruFocus considers Arbutus Biopharma to be Possible Value Trap.
Key valuation signals for ABUS:
Quick Ratio: 54.26 (378% above median its 10-year median of 11.35)
GF Value™: $51.42 vs. price of $4.36 (91.5% below fair value)
Industry Position: 1407.2% above the Biotechnology median (#19 of 1417)
No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
53GF Score
Get the complete analysis for ABUS
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABUS has been successfully added to your 
